Why would pharmaceutical companies manufacture single-enantiomer drugs?

Pharmaceutical companies manufacture single-enantiomer drugs to enhance therapeutic efficacy and reduce side effects. Enantiomers can have different biological activities, so isolating the more effective form can improve patient outcomes. Additionally, single-enantiomer drugs may lead to better regulatory approval and market differentiation, as well as potentially lower dosage requirements, which can be more cost-effective for both patients and healthcare systems.